Date : 25 May 2026

| Company | Headquarters | Latest Update |
| Abcam | United States | In April 2026, Abcam, a Danaher company and a global provider of validated antibodies and assay solutions, announced SimpleStep Ignite ELISA, a next-generation chemiluminescent immunoassay platform intended for researchers who require rapid and higher-quality decisions |
| Bio-Rad Laboratories, Inc. | United States | Bio-Rad has expanded its portfolio of recombinant monoclonal anti-idiotypic antibodies and SpyCatcher reagents, enhancing support for bioanalytical assay development and antibody drug research. |
| Merck KGaA | Germany | Merck offers an incessantly increasing, ISO-certified catalog of primary antibodies designed particularly for immunohistochemistry (IHC) on formalin-fixed, paraffin-embedded (FFPE) tissues. |
| Agilent Technologies, Inc. | United States | In March 2026, Agilent Technologies, a search organization, entered into a definitive agreement to acquire Biocare Medical, a worldwide leader in clinical pathology services, for $950 million in an all-cash transaction. |
| Thermo Fisher Scientific Inc. | United States | Thermo Fisher offers a advance suite of tools to allow deeper, more particular, and highly multiplexed tissue analysis. |
R&D:
Manufacturing Processes:
Patient Services:
The global immunohistochemistry market size was estimated at USD 3.42 billion in 2025 and is predicted to increase from USD 3.73 billion in 2026 to approximately USD 8.05 billion by 2035, expanding at a CAGR of 8.94% from 2026 to 2035.

Speak with a healthcare analyst about your research, consulting, or platform needs.